Rigel Pharmaceuticals' Q2 2025: Unpacking Contradictions in Tavalisse Growth and GAVRETO Sales Dynamics

TAVALISSE growth dynamics, TAVALISSE sales growth and affordability impact, patent litigation and ANDA filers, GAVRETO sales dynamics are the key contradictions discussed in Rigel Pharmaceuticals' latest 2025Q2 earnings call.



Revenue Growth and Product Sales:
- Rigel Pharmaceuticals reported net product sales of over $58 million in Q2 2025, an increase of 76% year-over-year.
- The growth was driven by increased sales across all commercial products, improved patient affordability in 2025, and favorable gross to net dynamics.

Commercial Product Performance:
- TAVALISSE generated $40.1 million in net product sales in Q2 2025, reflecting a 52% year-over-year increase.
- Growth was attributed to strong new patient demand and increased carryover demand from prior quarters, accelerated by improved patient affordability.

Financial Outlook and Guidance:
- Rigel raised its total revenue guidance for 2025 to between $270 million and $280 million, reflecting 45% to 52% year-over-year growth.
- This increase was driven by anticipated growth in net product sales and contract revenues from collaborations, exceeding the previous growth rate of approximately 30% over the last few years.

Development Pipeline Progress:
- R289, a novel dual IRAK1/4 inhibitor, completed enrollment in the dose escalation part of its Phase 1b study in MDS in July 2025.
- The progress was driven by promising clinical profile and favorable regulatory designations like Fast Track and Orphan Drug, which provide expedited regulatory pathways and potential priority review.